Physician profile
Roydon Steinke
NPI 1003931304
$3,460.72
in general payments reported to CMS, 2019-2025
29 companies · $461 in 2025
The $461 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,083 · 2020: $426 · 2021: $474 · 2022: $170 · 2023: $315 · 2024: $532 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,293 · Education: $14.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.62 |
| Education | $14.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $679.13 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $443.17 | 2023-2025 | |
| Lupin INC. | $328.89 | 2019-2020 | |
| Pfizer INC. | $280.69 | 2019-2024 | |
| Hologic Sales and Service, LLC | $198.12 | 2019-2025 | Omni Hysteroscope, Acessa Provu System, Thinprep 2000 Processor |
| Astellas Pharma US INC | $146.92 | 2023-2025 | Veozah |
| Angiodynamics, INC. | $142.85 | 2019 | |
| Amag Pharmaceuticals, INC. | $141.57 | 2019 | |
| Aspira Women'S Health INC | $133.12 | 2019 | |
| Sumitomo Pharma America, INC. | $102.23 | 2023-2025 | Myfembree |
| Coloplast Corp | $91.77 | 2024 | |
| Millicent US INC | $83.36 | 2024-2025 | Intrarosa, Femring |
| Myovant Sciences INC. | $79.74 | 2021-2022 | |
| Allergan, INC. | $72.81 | 2019-2020 | |
| Avion Pharmaceuticals | $65.62 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $64.13 | 2024 | Axonics |
| Bard Access Systems, INC. | $52.32 | 2019 | |
| Therapeuticsmd, INC. | $50.38 | 2020 | |
| Becton, Dickinson and Company | $49.86 | 2025 | |
| Agile Therapeutics, INC. | $48.46 | 2021-2023 | Twirla |
| Scynexis, INC. | $42.37 | 2022 | |
| Minerva Surgical, INC | $31.44 | 2019 | |
| Roche Diagnostics Corporation | $23.38 | 2019 | |
| Ethicon US, LLC | $20.80 | 2025 | Stratafix, Surgiflo Hemostatic Matrix, Surgicel Nu-Knit |
| Shield Therapeutics INC | $20.19 | 2024 | |
| Organon LLC | $18.87 | 2024 | |
| Vifor Pharma, INC. | $17.22 | 2019 | |
| Boston Scientific Corporation | $16.31 | 2025 | Axonics |
| Daiichi Sankyo INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roydon Steinke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.